That says: 7.2 Oral Medications ZEPBOUND delays gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications
network adequacy) are considerations in the negotiations between hospitals and payers and network needs involve anticipated patient utilization, we do not believe that hospitals and payers would consider anticipated patient utilization when negotiating contracts without considering the resources necessary (that is, costs) to provide those items and services for that level of patient utilization anticipated
Here are some key points about Zepbound: Composition and function: Contains tirzepatide, a compound also present in the diabetes medication Mounjaro Includes semaglutide and an additional hormone, GIP, to increase insulin secretion further and decrease appetite Acts as a dual agonist, activating both GLP-1 and GIP receptors Dosage and administration: Administered as a 2.5 mg weekly injection for the first month, then potentially increased to 5 mg weekly Dosage can be adjusted, with a maximum of 15 mg per week depending on individual needs and doctors guidance Indications and usage: Approved for use in adults 18 years and older with a body mass index (BMI) of 30 or higher (obese), or a BMI of 27 or higher (overweight) with at least one weight-related health condition To be used alongside a reduced-calorie diet and increased physical activity for optimal results Continuous usage may be necessary for maintaining weight loss, and patients should consider the benefits in relation to potential side effects and costs The efficacy of Zepbound in aiding weight loss is notable, with clinical trials showcasing significant results
In terms of weight loss, Mounjaro helped participants lose an average of 7.7 kg (17 lb) to 11.4 kg (25 lb), compared to 5.9 kg (13 lb) with Ozempic
But many still have efficacy claims with respect to GLP-1 products more generally that were not named in their letters
Biliary atresiaemerging diagnostic and therapy opportunities
